Remove Arcturus Remove Develop Remove Venture Capital
article thumbnail

Arcturus Gets $11M For 3D Video Editing Tools

socalTECH

Los Angeles-based Arcturus, a developer of 3D video editing tools, said Wednesday afternoon that it has raised $11M in a Series A funding round. The funding was led by Cloudtree Ventures, and also included Autodesk and Epic Games. The startup is led by CEO Kamal Mistry.

Arcturus 100
article thumbnail

Arcturus Therapeutics Gets $220M More In Support For Vaccine Efforts

socalTECH

San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds.

Arcturus 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Arcturus Get Exit At Pliant

socalTECH

Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. Arcturus first invested in Pliant in 2007. SanDisk is a major manufacturer of flash memory.

Arcturus 150
article thumbnail

Arcturus Therapeutics Gets $5M

socalTECH

San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. Names of those capital sources were not announced.

Arcturus 153
article thumbnail

Arcturus Therapeutics Gets $1.3M

socalTECH

San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech'

Arcturus 138
article thumbnail

Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More

Xconomy

A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. But the results, touted as positive, left more questions than answers.

Help 58